BIOCHEMICAL PROFILE AND VARIOUS TREATMENT MODALITIES OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)

Vinod Kumar¹, Ritu Bhagat²

¹MD, Department of Medicine, GMC, Jammu, Jammu and Kashmir, India.

²MD, Department of Pathology, GMC, Jammu, Jammu and Kashmir, India.

ABSTRACT

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized condition that may progress to end stage liver disease. Although non-alcoholic steatohepatitis (NASH) was considered relatively uncommon prior to middle of last decade, over the past few years there has been an explosion of studies on various aspects of NASH with one study reporting that after hepatitis C, NASH was the most common diagnosis in patients presenting largely with persistent abnormalities of liver function tests. We wanted to study the biochemical profile and various treatment modalities in patients of non-alcoholic steatohepatitis (NASH).

METHODS

The present study was carried out on 60 patients of NASH over a period of one year at Pathology Department of GMC, Jammu, which is a tertiary care centre. All patients with NASH were screened for various risk factors associated with NASH. Detailed history was taken, and thorough clinical examination was done. Required investigations were done such as Hb, TLC, DLC, blood sugar, renal function tests, complete liver tests, serum lipid profile, viral markers (HBsAg and Anti-HCV) and ANA. Ultrasound abdomen for hepatobiliary system was done to diagnose the patients of NASH.

RESULTS

Out of 60 patients, 28 (46.66%) were males and 32 (53.32%) were females. 85% of the patients were in the age group of 31-70 years. Out of 60 patients only 16 patients followed regularly and remained under close supervision.

CONCLUSIONS

In the present study, it was found that obesity was present in 46.6% cases whereas 50% patients were hyperlipidaemic. 38% patients were suffering from diabetes. It was found that there was marked symptomatic and biochemical improvement in those who were on strict dietary control and on regular follow up.

HOW TO CITE THIS ARTICLE: Kumar V, Bhagat R. Biochemical profile and various treatment modalities of patients with non-alcoholic steatohepatitis (NASH). J. Evolution Med. Dent. Sci. 2019;8(17):1405-1407, DOI: 10.14260/jemds/2019/312

BACKGROUND

Non-alcoholic fatty liver disease refers to wide spectrum of liver damage ranging from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. Steatohepatitis represents only a stage within the spectrum of non-alcoholic fatty liver disease.^[1] Ludwig et al introduced term non-alcoholic steatohepatitis to describe liver disease that is histologically indistinguishable from alcoholic hepatitis but occurs in persons who do not consume excess alcohol.^[2] NAFLD is defined as fat accumulation in liver exceeding 5% to 10% by weight. Inherent to defining NAFLD and NASH is threshold at which steatohepatitis become alcohol related. Many centers accepts upper limit of 20-40 gm/day in men and 20 gm/day in women.^[3] NAFLD is found in 70% of obese and 35% of lean patients. NASH is found in 18.5% of obese and 2.7% of lean patients. There is even distribution of NASH among men and women.

'Financial or Other Competing Interest': None.

Submission 13-03-2019, Peer Review 16-04-2019,

Acceptance 23-04-2019, Published 29-04-2019.

Corresponding Author:

Dr. Ritu Bhagat,

D/o. K. C. Bhagat,

209 Colonel Colony,

Talab Tillo-Bohri,

Jammu-180001,

Jammu and Kashmir, India.

E-mail: drvkad76@gmail.com

DOI: 10.14260/jemds/2019/312

METHODS

The present work is a hospital based cross-sectional study that included 60 patients of NASH registered with GMC, Jammu for a period of one year. All patients with NASH were screened for various risk factors associated with NASH. Detailed history was taken, and thorough clinical and biochemical profile was done. Necessary investigations like Hb, TLC, DLC, blood sugar, renal function tests, complete liver tests, serum lipid profile, viral markers (HBsAg and Anti HCV) and ANA were done. Ultrasound abdomen for hepatobiliary system was done to diagnose the patients of NASH. Got approval from IEC and consent was taken from all patients.

Inclusion Criteria

1. Ultrasonographically proven fatty liver.
2. Deranged liver function tests.
3. No significant alcohol intake i.e. <20 gm/day.
4. Absence of other relevant liver disease.

Exclusion Criteria

1. Daily alcohol intake i.e. >20 gm/day.
2. Use of amiodarone, steroids, tamoxifen, methotrexate or high dose oestrogen.
3. Jejunal bypass or extensive small bowel resection.
4. Other known liver disease.
5. Malignancy.

Statistical Methods

The statistical package for social science {SPSS} version 20 will be used for data analysis. Mean, median, and SD are used to describe quantitative data. Qualitative data are summarized using frequency and percentage.

RESULTS

Age Group in Years	Males		Females		Total	
	No.	%	No.	%	No.	%
10-30	5	8.33	2	3.33	7	11.66
31-50	17	28.33	16	26.66	33	55.0
51-70	6	10.0	12	20.0	18	30.0
>70	0	0.0	2	3.33	2	3.33
Total	28	46.66	32	53.32	60	100

Table 1. Age and Sex Distribution

Out of 60 patients, 28 were males and 32 were females. Majority of patients were in the group of 31-50 years (55%) followed by that in 51-70 years (30%). Thus, 85% of the patients were in the age of 31-70 years.

Body Mass Index	No. of Patients	
	Males	Female
18.5-24.9	4 (14.28%)	5 (15.62%)
25-29.9	8 (28.56%)	15 (46.87%)
30-34.9	14 (50.02%)	12 (37.51%)
35-39.9	2 (7.14%)	0
Total	28 (100%)	32 (100%)

Table 2. Specific Classification of BMI

Tests	No. of Patients	
	Male	Female
Increased Serum Bilirubin	13	14
Increased AST	24	27
Increased ALT	28	29
AST: ALT > 1	2	3
Increased Alk. PO ₄	6	4
Total *	73	77

Table 3. Liver Function Tests

Fasting Blood Sugar	No. of Patients	
	Male	Female
< 100	9 (32.14%)	14 (43.75%)
100-125	9 (32.14%)	5 (15.62%)
≥126	10 (35.72%)	13 (40.63%)
Total	28 (100%)	32 (100%)

Table 4. Fasting Blood Sugar

Risk Factors	No. of Patients	
	Male	Female
Obesity	16	12
Hyperlipidaemia	17	13
Diabetes Mellitus	10	13
Total*	43	38

Table 5. Associated Risk Factors

*The numbers don't add up to 60 since more than one sign/symptom was present in single patient. In the present study it was found that obesity, hyperlipidaemia and diabetes mellitus were significantly associated with the NASH (n=60)

Variables	Mean	Range
Age (y)	44	22-75
Sex Female (%)	32%	
Anthropometric Data		
• Obesity (%)	46%	
• Overweight (%)	39%	
• Lean (%)	15%	
• Body weight	75.3 kg	56-110 kg
• BMI	29.18	20.0-39.9
Waist Circumference		
• Men > 102 cm	10/28 (35%)	
• Women > 88 cm	25/32 (78%)	
S. Bilirubin	1.4	0.5-8.2
AST	73.21	28-285
ALT	102.35	33-240
Alk. PO ₄	97.75	59-176
Glucose Tolerance		
• Diabetes Mellitus	23/60 (38.3%)	
• Impaired Glucose Fasting	14/60 (23.3%)	
Hyperlipidaemia	30/60 (50%)	

Table 6

Author	n	Mean Age	Female %	Diabetes %	Obesity %	Hyperlipidaemia %
Ludwig	20	54	65	50	90	67
Diehl	39	52	81	55	71	20
Lee	49	53	78	51	69	Not Reported
Powell	42	49	83	36	95	81
Bacon	33	47	42	21	39	21
Matteoni	132	53	53	33	70	92
Angulo	144	51	67	28	60	27
Our Study	60	44	53	38	46	43

Table 7

Various Treatment Modalities

16 patients followed regularly and remained under close supervision and were evaluated after 6 months of treatment. They were asked to cut down the intake of fats and avoid red meat. They were asked for daily brisk walking for one hour each in the morning and evening. Out of 60, 56 patients were prescribed vitamin E 800 IU/day and 4 patients were put on metformin 500 mg/day. After six months, they were re-evaluated, and it was found that their raised enzymes reduced markedly.

DISCUSSION

Present study was undertaken in 60 patients to assess the biochemical profile and various treatment modalities of patients with non-alcoholic steatohepatitis. Out of which 28 (46.66%) were males and 32 (53.32%) were females. Maximum patients were in the age group of 31-50 years (55%) followed by that in 51-70 years (30%). Thus 85% of the patients in the age group of 31-70 years.

In our study 46.6% (28/60) patients were found to be obese and 38.3% (23/60) were found to be overweight. Thus, total of 84.9% (51/60) patients had BMI >25. 9 (15%) patients were found to have BMI <25. Ludwig et al in his study found

that 90% of patients with NASH were obese^[4] whereas Lee in demonstrated in his study that 69% patients with NASH were obese.^[5] Bacon et al in their study that 39% patients of NASH were obese.^[6] Angulo et al found in their study that 60% of patients with NASH were obese.^[7]

In our study 50% (30/60) patients were found to be hyperlipidaemic. Out of 30, 16 patients had raised VLDL, 9 patients had raised triglycerides and 5 patients had raised both VLDL and triglycerides. Ludwig et al in their study found that 67% of patients of NASH were hyperlipidaemic.^[4] Diehl et al in their study found that 20% of patients of NASH were hyperlipidaemic whereas Bacon et al in their study found 21% of patients of NASH to be hyperlipidaemic.^[6] Angulo et al demonstrated that 27% patients of NASH were hyperlipidaemic.^[7]

In our study of 38.3% (23/60) patients were found to be diabetic. Ludwig et al found 50% of patients of NASH to be diabetic^[4] whereas Diehl et al demonstrated in their study that 55% patients of NASH were diabetic. In the study conducted by Powell et al, 36% of patients of NASH were found to be diabetic.^[8] Bacon et al demonstrated that 21% of patients were diabetic.^[6] Angulo et al found 28% of patients of NASH to be diabetic.^[7]

Out of 60 patients only 16 patients followed regularly and remained under close supervision, they were asked to cut down the intake of fats and avoid red meat. They were asked for daily brisk walking for one hour each in the morning and evening. 56 patients were put on vitamin E 800 IU/day. 4 patients were put on metformin 500 mg/day. But the patients put on metformin left the study on their own because they were told by someone that metformin is used to decrease blood sugar. All patients were asked for regular follow up but only 16 patients completed study. They were evaluated at the end of six months and it was found that there was marked symptomatic and biochemical improvement.

CONCLUSION

Obesity was present in 46.6% cases whereas 50% patients were hyperlipidaemic. 38% patients were suffering from diabetes. It was found that there was marked symptomatic and biochemical improvement in those who were on strict dietary control and on regular follow up.

REFERENCES

- [1] Angulo P. Non-alcoholic fatty liver disease. *NEJM* 2002;346(16):1221-31.
- [2] Caldwell SH, Oelsner DH, Lezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. *Hepatology* 1999;29(3):664-9.
- [3] Neuschwander-Tetri BA, Caldwell SH. Non-alcoholic steatohepatitis: summary of an AASLD single topic conference. *Hepatology* 2003;37(5):1202-19.
- [4] Ludwig J, Viggiano TR, McGill DB, et al. Non-alcoholic steatohepatitis: mayo clinic experience with a hitherto unnamed disease. *Mayo Clin Proc* 1980;55(7):434-8.
- [5] Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. *Hum Pathol* 1989;20(6):594-8.
- [6] Bacon BR, Faravash MJ, Janney CG, et al. Non-alcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* 1994;107(4):1103-09.
- [7] Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. *Hepatology* 1999;30(6):1356-62.
- [8] Powell EE, Cooksley WGE, Hanson R, et al. The natural history of non-alcoholic steatohepatitis: a follow up study of forty two patients for up to 21 years. *Hepatology* 1990;11(1):74-80.